S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
5 Hypergrowth Stocks to Buy Now (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
5 Hypergrowth Stocks to Buy Now (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
"Prepare for Five Years of Famine" (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
5 Hypergrowth Stocks to Buy Now (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
5 Hypergrowth Stocks to Buy Now (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
"Prepare for Five Years of Famine" (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
5 Hypergrowth Stocks to Buy Now (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
5 Hypergrowth Stocks to Buy Now (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
"Prepare for Five Years of Famine" (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
5 Hypergrowth Stocks to Buy Now (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
5 Hypergrowth Stocks to Buy Now (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
"Prepare for Five Years of Famine" (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Canada approves largest telecom deal in country's history
NASDAQ:EXAS

Exact Sciences - EXAS Stock Forecast, Price & News

$67.81
+1.55 (+2.34%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$65.81
$68.38
50-Day Range
$60.05
$70.77
52-Week Range
$29.27
$76.94
Volume
3.12 million shs
Average Volume
2.17 million shs
Market Capitalization
$12.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.14

Exact Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.69 Rating Score
Upside/​Downside
9.3% Upside
$74.14 Price Target
Short Interest
Healthy
6.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.56mentions of Exact Sciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$3.92 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.76) to ($2.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

472nd out of 1,004 stocks

Medical Laboratories Industry

15th out of 24 stocks


EXAS stock logo

About Exact Sciences (NASDAQ:EXAS) Stock

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Stock News Headlines

The Market Crash Shield is A.I.
Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. pixel
Cathie Wood Watch: Ark Gets Back into Intuit
The Market Crash Shield is A.I.
Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. pixel
Cathie Wood Watch: Ark Buys Block, Tesla
Cathie Wood Watch: Ark Buys Robinhood Again
Cathie Wood Watch: Ark Buys Robinhood
Cathie Wood Watch: Ark Again Pares DraftKings Stake
See More Headlines
Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Company Calendar

Last Earnings
2/21/2023
Today
4/01/2023
Next Earnings (Estimated)
4/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXAS
CUSIP
30063P10
Employees
6,400
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$74.14
High Stock Price Forecast
$92.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+9.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
13 Analysts

Profitability

Net Income
$-623,510,000.00
Pretax Margin
-30.35%

Debt

Sales & Book Value

Annual Sales
$2.08 billion
Book Value
$17.13 per share

Miscellaneous

Free Float
175,900,000
Market Cap
$12.09 billion
Optionable
Optionable
Beta
1.42

Social Links


Key Executives

  • Kevin T. ConroyKevin T. Conroy
    Chairman, President & Chief Executive Officer
  • Jeffrey Thomas ElliottJeffrey Thomas Elliott
    Executive VP, Chief Operating & Financial Officer
  • Sandra Statz
    Senior VP-Clinical & Regulatory Affairs
  • Paul J. Limburg
    Co-Chief Medical Officer & Screening
  • Frederick Baehner
    Co-Chief Medical Officer & Precision Oncology













EXAS Stock - Frequently Asked Questions

Should I buy or sell Exact Sciences stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EXAS shares.
View EXAS analyst ratings
or view top-rated stocks.

What is Exact Sciences' stock price forecast for 2023?

13 analysts have issued 1-year target prices for Exact Sciences' stock. Their EXAS share price forecasts range from $55.00 to $92.00. On average, they predict the company's share price to reach $74.14 in the next year. This suggests a possible upside of 9.3% from the stock's current price.
View analysts price targets for EXAS
or view top-rated stocks among Wall Street analysts.

How have EXAS shares performed in 2023?

Exact Sciences' stock was trading at $49.51 at the start of the year. Since then, EXAS stock has increased by 37.0% and is now trading at $67.81.
View the best growth stocks for 2023 here
.

Are investors shorting Exact Sciences?

Exact Sciences saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 12,380,000 shares, a decrease of 5.3% from the February 28th total of 13,070,000 shares. Based on an average trading volume of 2,510,000 shares, the short-interest ratio is currently 4.9 days.
View Exact Sciences' Short Interest
.

When is Exact Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023.
View our EXAS earnings forecast
.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings results on Tuesday, February, 21st. The medical research company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.90) by $0.18. The medical research company had revenue of $553 million for the quarter, compared to analyst estimates of $525.61 million. Exact Sciences had a negative net margin of 29.92% and a negative trailing twelve-month return on equity of 19.76%. The business's revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.28) earnings per share.

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences updated its FY 2023 earnings guidance on Tuesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.27 billion-$2.31 billion, compared to the consensus revenue estimate of $2.29 billion.

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How do I buy shares of Exact Sciences?

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $67.81.

How much money does Exact Sciences make?

Exact Sciences (NASDAQ:EXAS) has a market capitalization of $12.09 billion and generates $2.08 billion in revenue each year. The medical research company earns $-623,510,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis.

How many employees does Exact Sciences have?

The company employs 6,400 workers across the globe.

Does Exact Sciences have any subsidiaries?
The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..
Read More
How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701.

This page (NASDAQ:EXAS) was last updated on 4/1/2023 by MarketBeat.com Staff